Shanglan Gao1, Yan Yang2, Yun Fu2, Weidong Guo2, Guowei Liu2. 1. Department of Critical Care Medicine, the Central Hospital of Xinxiang City, Xinxiang, China. Electronic address: shanglangao@126.com. 2. Department of Critical Care Medicine, the Central Hospital of Xinxiang City, Xinxiang, China.
Abstract
OBJECTIVE: The objective of this study is to evaluate the diagnostic and prognostic value of myeloid-related protein complex 8/14 (MRP8/14) in septic patients in intensive care units. METHODS: Fifty-three cases of healthy people, 72 cases of systemic inflammatory response syndrome patients, 74 cases of sepsis patients, 78 cases of severe sepsis patients, and 76 cases of septic shock patients were enrolled in our hospital. Serum MRP8/14 was detected by enzyme-linked immunosorbent assay, and Mortality in Emergency Department Sepsis (MEDS) score was calculated at enrollment. The receiver operating characteristic curve was used to analyze the diagnostic value of MRP8/14 for sepsis. The prognostic values of MRP8/14 were compared with MEDS score. A 28-day follow-up was performed for all patients. RESULTS: Serum MRP8/14 level of control group, systemic inflammatory response syndrome group, sepsis group, severe sepsis group, and septic shock group was (834.135 ± 251.662), (2343.213 ± 901.850), (3163.617 ± 912.821), (3941.326 ± 850.490), and (4131.326 ± 950.439) ng/mL, respectively. Myeloid-related protein complex 8/14 level increased with sepsis severity. The area under the receiver operating characteristic curves of MRP8/14 for sepsis was 0.901 (95% confidence interval, 0.852-0.942).The area under the receiver operating characteristic curves of MRP8/14 was greater than that of MEDS score in predicting 28-day mortality. Serum MRP8/14 level was significantly higher in nonsurvivors than survivors at 28 days' follow-up. In addition, the level of MRP8/14 was much higher in septic patients with acute kidney injury (AKI) than those without AKI. CONCLUSIONS: Myeloid-related protein complex 8/14 is valuable for diagnosis and prognostication of sepsis and septic patients with AKI in the intensive care unit.
OBJECTIVE: The objective of this study is to evaluate the diagnostic and prognostic value of myeloid-related protein complex 8/14 (MRP8/14) in septicpatients in intensive care units. METHODS: Fifty-three cases of healthy people, 72 cases of systemic inflammatory response syndrome patients, 74 cases of sepsispatients, 78 cases of severe sepsispatients, and 76 cases of septic shockpatients were enrolled in our hospital. Serum MRP8/14 was detected by enzyme-linked immunosorbent assay, and Mortality in Emergency Department Sepsis (MEDS) score was calculated at enrollment. The receiver operating characteristic curve was used to analyze the diagnostic value of MRP8/14 for sepsis. The prognostic values of MRP8/14 were compared with MEDS score. A 28-day follow-up was performed for all patients. RESULTS: Serum MRP8/14 level of control group, systemic inflammatory response syndrome group, sepsis group, severe sepsis group, and septic shock group was (834.135 ± 251.662), (2343.213 ± 901.850), (3163.617 ± 912.821), (3941.326 ± 850.490), and (4131.326 ± 950.439) ng/mL, respectively. Myeloid-related protein complex 8/14 level increased with sepsis severity. The area under the receiver operating characteristic curves of MRP8/14 for sepsis was 0.901 (95% confidence interval, 0.852-0.942).The area under the receiver operating characteristic curves of MRP8/14 was greater than that of MEDS score in predicting 28-day mortality. Serum MRP8/14 level was significantly higher in nonsurvivors than survivors at 28 days' follow-up. In addition, the level of MRP8/14 was much higher in septicpatients with acute kidney injury (AKI) than those without AKI. CONCLUSIONS: Myeloid-related protein complex 8/14 is valuable for diagnosis and prognostication of sepsis and septicpatients with AKI in the intensive care unit.
Authors: Juan C Mira; Lori F Gentile; Brittany J Mathias; Philip A Efron; Scott C Brakenridge; Alicia M Mohr; Frederick A Moore; Lyle L Moldawer Journal: Crit Care Med Date: 2017-02 Impact factor: 7.598
Authors: Scott J Denstaedt; Joanna L Spencer-Segal; Michael W Newstead; Klaudia Laborc; Anne P Zhao; Alexander Hjelmaas; Xianying Zeng; Huda Akil; Theodore J Standiford; Benjamin H Singer Journal: J Immunol Date: 2018-03-21 Impact factor: 5.422
Authors: Petrus Linge; Paul R Fortin; Christian Lood; Anders A Bengtsson; Eric Boilard Journal: Nat Rev Rheumatol Date: 2018-03-21 Impact factor: 20.543